SAN DIEGO, May 8, 2023 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and to clear human papillomavirus and related pre-cancerous cervical lesions, today announced that...
— PRTX007 was shown to be well-tolerated with a favorable safety profile for all analyzed cohorts in the Phase 1 study — — Stable systemic immune induction was observed in the 750mg cohort, with CD8+ T cells and NK cell activation significantly increasing from...
SAN DIEGO, March 14, 2023 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for the clearance of human papillomavirus and related pre-cancerous cervical lesions, today...
SAN DIEGO, April 8, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for the clearance of human papillomavirus and related pre-cancerous cervical lesions, today...
SAN DIEGO, March 28, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for clearing human papillomavirus-driven pre-cancerous cervical lesions, today announced that...
— PRTX007 exhibits activation of the innate immune system in both cellular and murine animal models against respiratory syncytial virus (RSV) — — Findings demonstrate broad-spectrum antiviral activity and suitability of PRTX007 as a clinical candidate to support...
SAN DIEGO, March 10, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the...
SAN DIEGO, February 24, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the...
— Oral administration of PRTX007 exhibits favorable safety profile, rapid conversion to TLR7 agonist PRX034, and activation of the innate immune system, without an increase in proinflammatory factors — SAN DIEGO, February 14, 2022 – Primmune Therapeutics, a biotech...
SAN DIEGO, February 7, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat viral diseases and cancers, today announced that they will present data related to PRTX007, a novel, orally administered, small molecule...
